Rallybio shareholders approve reverse stock split in a range from 1-for-2 to 1-for-9
Key Facts
Rallybio shareholders at their annual meeting on November 4 approved an amendment allowing a reverse stock split at a ratio ranging from 1-for-2 to 1-for-9, with the parties to determine the final ratio. The filing does not establish that the company selected a 1-for-2 ratio or carried out the split; rather, the decision sets a range of authority available to it in agreement with Avenzo. A total of 4,768,828 shares voted for the proposal, against 21,477 shares, while holders of 15 shares abstained. The companies said they do not intend to implement the split before the merger closes. This ties the timing of the action to completion of the transaction, rather than treating it as already implemented or as a publicly stated key condition for completing the merger.
The November 4 filing had expected the merger to close on November 6, subject to the satisfaction or waiver of the existing closing conditions. The company later reported that the transaction had not closed on that expected date, leaving its timing uncertain based on the information available here. The delay also meant Rallybio did not deposit the announced cash distribution funds with Computershare on November 5. The company said the payment date and the ex-distribution date could be delayed as a result. Accordingly, the timing of the split, as announced by the companies, is linked to the closing of the transaction, which did not occur on the previously expected date.
On ownership, shareholders approved issuing shares to Avenzo shareholders representing more than 20% of Rallybio's outstanding shares before the merger, resulting in a change of control of the company. The merger prospectus estimated that former Avenzo shareholders would own about 56.6% of the combined company, compared with about 2.8% for former Rallybio shareholders, while about 40.6% would go to concurrent private financing investors. These percentages are based on the prospectus's assumptions, which it said are subject to adjustment. One factor that could change them is Rallybio's final net cash at closing. The estimates therefore reflect the expected ownership structure under those assumptions, not final percentages confirmed after the transaction is completed.
The transaction assumptions included concurrent private financing of $215 million and a fixed valuation of $300 million for Avenzo. The prospectus also assumed a valuation of $15 million for Rallybio after accounting for the expected cash distributions. These assumptions help explain part of the difference between the former shareholders' stakes in the two companies within the merged entity, alongside the stake for concurrent financing investors. However, the prospectus said ownership percentages may be subject to adjustments, including those related to Rallybio's final net cash at closing. These figures remain estimates tied to the transaction's terms and assumptions, not finalized stakes before completion.
RLYB closed at $15.66 in the November 9 session, according to EL7 data. The close came after the previously expected November 6 merger completion date, and as the company said its cash distribution date could be delayed. The available data do not include the session's high and low prices, so no trading range is given here. The closing price is for November 9 and, by itself, does not determine the effect of the split announcement or closing developments on the share's movement. The final split ratio and implementation date remain linked to an agreement between Rallybio and Avenzo and completion of the merger.